InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
0.8100
+0.0075 (0.93%)
At close: Jun 2, 2025, 4:00 PM
0.7808
-0.0292 (-3.60%)
After-hours: Jun 2, 2025, 7:56 PM EDT
InflaRx Employees
InflaRx had 74 employees as of December 31, 2024. The number of employees increased by 12 or 18.97% compared to the previous year.
Employees
74
Change (1Y)
12
Growth (1Y)
18.97%
Revenue / Employee
$1,895
Profits / Employee
-$653,200
Market Cap
54.88M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
IFRX News
- 5 days ago - InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga
- 6 days ago - InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewsWire
- 11 days ago - InflaRx to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 26 days ago - InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - InflaRx to Report First Quarter 2025 Results on May 7, 2025 - GlobeNewsWire
- 2 months ago - InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones - GlobeNewsWire
- 3 months ago - InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewsWire
- 3 months ago - InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewsWire